How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

244 results for

Emergency Pediatric Dosing 12-14 kilogram

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

141. Diagnosis and Management of Cerebral Venous Thrombosis

recommendations are provided for the diagnosis, management, and prevention of recurrence of cerebral venous thrombosis. Recommendations on the evaluation and management of cerebral venous thrombosis during pregnancy and in the pediatric population are provided. Considerations for the management of clinical complications (seizures, hydrocephalus, intracranial hypertension, and neurological deterioration) are also summarized. An algorithm for diagnosis and management of patients with cerebral venous sinus (...) (eg, thrombophilias, inflammatory bowel disease), transient situations (eg, pregnancy, dehydration, infection), selected medications (eg, oral contraceptives, substance abuse), and unpredictable events (eg, head trauma) are some predisposing conditions. , Given the diversity of causes and presenting scenarios, CVT may commonly be encountered not only by neurologists and neurosurgeons but also by emergency physicians, internists, oncologists, hematologists, obstetricians, pediatricians, and family

2011 Congress of Neurological Surgeons

142. Short Bowel Syndrome Research Study for Children Up To 17 Years of Age on Parenteral Nutrition

Provider, Investigator) Primary Purpose: Treatment Official Title: A 24-Week Double-blind, Safety, Efficacy, and Pharmacodynamic Study Investigating Two Doses of Teduglutide in Pediatric Subjects Through 17 Years of Age With Short Bowel Syndrome Who Are Dependent on Parenteral Support Actual Study Start Date : June 23, 2016 Actual Primary Completion Date : August 18, 2017 Actual Study Completion Date : August 18, 2017 Resource links provided by the National Library of Medicine available for: resources (...) ClinicalTrials.gov identifier (NCT number): NCT02682381 Sponsors and Collaborators Shire Investigators Layout table for investigator information Study Director: Shire Physician Shire Study Documents (Full-Text) Documents provided by Shire: [PDF] March 12, 2015 [PDF] June 22, 2015 [PDF] February 25, 2016 [PDF] March 15, 2016 [PDF] July 14, 2017 [PDF] October 6, 2015 More Information Go to Layout table for additonal information Responsible Party: Shire ClinicalTrials.gov Identifier: Other Study ID Numbers: TED-C14

2016 Clinical Trials

143. Aminopenicillins

. ) Conditions Infectious Enteritis ( ) VIII. Adverse effects Similar to s Maculopapular rash Onset 5-7 days after initiating medication Typically not IgE mediated (non-allergic) No immediate allergy (e.g. ), systemic symptoms or mucous membrane involvement Typically safe to use Amoxicillin in future if non-allergic rash alone Consider IgE if unclear rash etiology References Orman and Hayes in Herbert (2017) EM:Rap 17(7): 7-8 (modifications can decrease stools to 12%) Dose exactly by kilogram for children (...) Aminopenicillins Aminopenicillins Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Aminopenicillins Aminopenicillins Aka

2018 FP Notebook

144. Unfractionated Heparin

Heparin Aka: Unfractionated Heparin , Heparin From Related Chapters II. Mechanism Potentiates (AT III) See III. Dosing: Prophylactic for DVT Prevention Heparin 5000 Units SQ every 8-12 hours IV. Dosing: Therapeutic Dosing by Weight based Calculations Measure Total body weight (TBW) in kilograms Height in inches Calculate (LBW) in kilograms Male: 50 + 2.3 x (height in inches - 60) Female: 45 + 2.3 x (height in inches -60) Calculate Dosing Weight Non-Obese Dosing Weight (kg): TBW above Obese (TBW > 1.4 (...) Unfractionated Heparin Unfractionated Heparin Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Unfractionated Heparin Unfractionated

2018 FP Notebook

145. Gastrointestinal Complications (PDQ®): Health Professional Version

. Gastrointest Endosc 54 (2): 229-32, 2001. [ ] Martinez-Santos C, Lobato RF, Fradejas JM, et al.: Self-expandable stent before elective surgery vs. emergency surgery for the treatment of malignant colorectal obstructions: comparison of primary anastomosis and morbidity rates. Dis Colon Rectum 45 (3): 401-6, 2002. [ ] Ripamonti C, Bruera E: Palliative management of malignant bowel obstruction. Int J Gynecol Cancer 12 (2): 135-43, 2002 Mar-Apr. [ ] Potluri V, Zhukovsky DS: Recent advances in malignant bowel (...) chemotherapy.[ ] The large and small bowel are very sensitive to ionizing radiation. Although the probability of tumor control increases with the radiation dose, so does the damage to normal tissues. Acute side effects to the intestines occur at approximately 10 Gy. Because curative doses for many abdominal or pelvic tumors range between 50 and 75 Gy, enteritis is likely to occur.[ ] In this summary, unless otherwise stated, evidence and practice issues as they relate to adults are discussed. The evidence

2015 PDQ - NCI's Comprehensive Cancer Database

146. Management of Women with Obesity in Pregnancy

12. Care during childbirth 11 13. Postnatal care and follow-up after pregnancy 13 14. Local guidelines 15 15. Facilities and equipment 15 16. Education of health professionals 16 17. Areas for further research 17 18. Auditable standards 17 References 18 APPENDIX 1: Process for developing the consensus standards 22 APPENDIX 2: Levels and grades of evidence 26 APPENDIX 3: Maternal and fetal risks in women with a BMI =30 kg/m 2 compared to women with a healthy BMI 27 APPENDIX 4: Pre-pregnancy (...) of a number of serious adverse outcomes, including miscarriage, 6 fetal congenital anomaly, 7 thromboembolism, 8,9 gestational diabetes, 10 pre-eclampsia, 11 dysfunctional labour, 12 postpartum haemorrhage, 10 wound infections, 10 stillbirth 13,14 and neonatal death. 14-16 There is a higher caesarean section rate 17 and lower breastfeeding rate 18 in this group of women compared to women with a healthy BMI. There is also evidence to suggest that obesity may be a risk factor for maternal death

2010 Royal College of Obstetricians and Gynaecologists

147. Management of pancreatic exocrine insufficiency: Australasian Pancreatic Club recommendations

exocrine insufficiency Adapted from Domínguez-Muñoz. 4 Recommended doses of pancreatic enzyme replacement therapy in patients with pancreatic exocrine insufficiency Age group Initial recommended dose Maximum recommended dose Adults (≥ 18 years) 25 000–40 000 units lipase per meal 8,10 * 75 000–80 000 units lipase per meal 8,10 Children (4–17 years) 500–4000 units lipase per gram of dietary fat 11 OR 500 units lipase per kilogram of bodyweight per meal 12 * 10 000 units lipase per kg bodyweight per day (...) 12 Children (6 months to 3 years) 500–4000 units lipase per gram of dietary fat 11 OR 1000 units lipase per kilogram of bodyweight per meal 12 * 10 000 units lipase per kilogram of bodyweight per day 12 Infants (< 6 months) 500–1000 units lipase per gram of dietary fat 11 OR 2000–4000 units lipase per breastfeed or per 120 mL of infant formula 12 10 000 units lipase per kilogram of bodyweight per day 12 * Enzyme doses should be halved for snacks. James Toouli 1 Andrew V Biankin 2 Mark R Oliver 3

2010 MJA Clinical Guidelines

148. Jinarc - tolvaptan

kilogram MRI Magnetic resonance imaging n Number ND Not determined PASS Post authorisation safety study PD Pharmacodynamic P-gp P-glycoprotein PK Pharmacokinetic PKD Polycystic kidney disease PKD1, PKD2 Polycystin 1, 2 q.d Once daily QT QT interval QTc Corrected QT interval Rac Accumulation ratio RHD Recommended human dose RMP Risk management plan RPF Renal plasma flow SAP Statistical analysis plan SD Standard deviation SMQ Standardised medical query SmPC Summary of product characteristics ss Steady (...) . The immediate release formulation of tolvaptan 15 mg and 30 mg tablets is the same approved in 2009 in MAA as Samsca (EMA/H/C/980) for the treatment of hyponatremia. The 15 mg and 30 mg strengths are dose proportional with regard to the active Assessment Report EMA/154879/2015 Page 12/124 substance and excipients. The 45 mg and 90 mg strengths of tablets were designed to be quantitatively proportional with the 60-mg tablets. Given that tolvaptan is practically insoluble in water and shows no pH dependence

2015 European Medicines Agency - EPARs

149. Translarna - ataluren

and evening doses. Approximate intervals for dosing were to be 6 hours between morning and midday doses, 6 hours between midday and evening doses and 12 hours between the evening dose and the morning dose on the next day. Administration within 30 minutes after a meal was recommended. Study drug dosing was based on milligrams of drug per kilogram of body weight. The planned duration of treatment was 48 weeks. The use of corticosteroids was to be standardized as much as possible during the study in order (...) and 97.5 in dog). Following intravenous administration of a single dose to dogs, the systemic clearance averaged 123 ml/kg.hr and the volume of distribution at steady state (V ss ) was 0.21 l/kg. In a bioavailability study conducted in dogs with intravenous and oral dosing, low bioavailability (7%) was seen, which corresponded to the observed low urinary excretion in this species (12% of the dose). In mice and rats, the excretion via urine and bile indicated high bioavailability (40% urinary excretion

2014 European Medicines Agency - EPARs

150. Xigduo - dapagliflozin / metformin

, Combinations of oral blood glucose-lowering drugs (A10BD15) Therapeutic indication: Indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control Pharmaceutical form: Film-coated tablet Strengths: 5 mg / 850 mg and 5 mg / 1000 mg Route of administration: Oral use Packaging: blister (PVC/Aclar//Alu) Package size: 14, 28, 56 and 60 tablets 60 x 1 tablet (unit dose) 196 (2 x 98) tablets (multipack) Assessment report EMA/CHMP/620505 (...) European Association for the Study of Diabetes Assessment report EMA/CHMP/620505/2013 Page 6/105 eGFR Estimated glomerular filtration rate FDA Food and Drug Administration FDC Fixed dose combination FPG Fasting plasma glucose GLP Good Laboratory Practice HbA1c Haemoglobin A1c ICH International Conference on Harmonization IDF International Diabetes Federation IR Immediate release kg kilogram LOCF Last observation carried forward LT Long-term MAA Marketing Authorisation Application mg milligram mL

2014 European Medicines Agency - EPARs

151. ACR-ASNR Practice Guideline for the Performance and Interpretation of Cervicocerebral Computed Tomography Angiography (CTA)

arch, the origin and cervical course of the subclavian and carotid arteries, the Circle of Willis, and up to the vertex. In some patients, coverage can extend to include the complete aortic arch, the left atrium, the distal intracranial arteries, and the venous sinuses. In the pediatric population, anatomic coverage should be strictly limited to the vascular segments of interest, in order to keep the radiation dose as low as possible. Postprocessing of the CTA by either physicians or licensed (...) the CT scan and thus derive the full diagnostic benefit for the patient following X-ray irradiation, any CT scanner used for CTA must allow display and interpretation of the full 12 bits (from 1,000 to 3,095 Hounsfield units) of attenuation information. Additionally, the display field of view must be sufficient to allow an assessment of the vasculature of interest, the end-organ, and adjacent tissues. Appropriate emergency equipment and medications must be immediately available to treat adverse

2010 American Society of Neuroradiology

152. CPG on Acute Bronchiolitis

12 months, others also include successive episodes in the same patient). Acute bronchiolitis places considerable demand on healthcare resources, not only in primary care, where it generates a signi?cant number of consultations during both the acute and the sequelae phase, but also in hospitals, with major Accident & Emergency care requirements and a large number of admissions during epidemics. Of these cases, 5-16% will need to be admitted to a paediatric intensive care unit (PICU) 6 . In one (...) Consultant of the Neonatology Unit of Barcelona Clinical Hospital, President Elect of the World Association of Perinatal Medicine, Barcelona Rosario Cintora Cacho, paediatric nurse, Nursing Supervisor, Sant Joan de Déu Hospital, Barcelona Gemma Claret Teruel, paediatrician, Staff Physician of Emergency Department, Paediatrics Unit, Sant Joan de Déu Hospital, member of respiratory group of the Spanish Society for Paediatric Emergency Care (SEUP), Barcelona Eduardo González Pérez-Yarza, paediatrician, Head

2010 GuiaSalud

153. CPG on the Diagnosis, Treatment and Prevention of Tuberculosis

to diagnose extrapulmonary (pleural, meningeal, pericardial, lymphatic, abdominal) tubercu- losis? 11. What is the diagnostic performance of the various methods available to diagnose resistance to tuberculosis drugs? TREATING TUBERCULOSIS 12. In patients (adults and children) with pulmonary tuberculosis, what is the optimum duration of tuberculosis treatment? 13. In patients (adults and children) with pulmonary tuberculosis, are intermittent treatment regimens as effective as daily regimens? 14. Are fixed (...) of Interests 183 Appendix 6: Main Documents and Useful Resources 185 Appendix 7: Proposed Evaluation Indicators 187 Appendix 8: Table of Interactions of the Main Tuberculosis Drugs 189 Appendix 9: Combined Administration of Rifampicin or Rifabutin and Antiretrovirals 191 Appendix 10: Respiratory Isolation 195 Appendix 11: Reading Tuberculin Tests in Population Screening 197 Appendix 12: Side Effects and Monitoring of Treatment for Latent Infection 199 Appendix 13: Overall Assessment of Risk of Liver

2010 GuiaSalud

154. CPG on Attention Deficit Hyperactivity Disorder (ADHD) in the Child and Adolescent Population

of immediate release methylphenidate can be added to the treatment at breakfast and/or mid-afternoon, to thus adjust the total dose of methylphenidate in agreement with the weight of the child or adolescent with ADHD and with the clinical response.If a 12-hour therapeutic action is required and the child or adolescent with ADHD is not able to swallow tablets, extended release methylphenidate can be administered with pellet technology in the morning (opening the capsule) and in the afternoon, after school (...) 11. Dissemination and implementation 169 12. Future research recommendations 171 It has been 5 years since the publication of this Clinical Practice Guideline and it is subject to updating. 6 CLINICAL PRACTICE GUIDELINE ON ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN CHILDREN AND ADOLESCENTS Appendices Appendix 1 Levels of evidence and degrees of recommendation 176 Appendix 2 Diagnostic criteria for ADHD 177 Appendix 3 Information for patients, family members and educators 180 Appendix 4

2010 GuiaSalud

155. A Study of Pediatric Patients With Attention Deficit/Hyperactivity Disorder

provided by the National Library of Medicine related topics: Arms and Interventions Go to Arm Intervention/treatment Experimental: Edivoxetine All enrolled participants were administered starting dose of 0.1 milligram per kilogram per day (mg/kg/day), or participant specific known stable dose, rollover participants (LNBJ [No NCT number]) and (LNBF [NCT00922636]), up to 0.3 mg/kg/day, oral, daily for up to 5 years. Drug: Edivoxetine 0.1 mg/kg/day or participant specific known stable dose, rollover (...) A Study of Pediatric Patients With Attention Deficit/Hyperactivity Disorder A Study of Pediatric Participants With Attention Deficit/Hyperactivity Disorder - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more

2009 Clinical Trials

156. Eculizumab Pharmacokinetics/Pharmacodynamics Study in Pediatric/Adolescent PNH Subjects

meningitidis (N. men), Streptococcus pneumoniae (S. pneumo), and Haemophilus influenzae (H. influ) vaccinations at least 14 days prior to first dose of study drug, or was vaccinated and received treatment with appropriate antibiotics until 14 days after the vaccinations. Participants received eculizumab intravenously (IV) based on their weight. Eculizumab was administered via an IV infusion at a rate of 5 to 10 milliliters (mL) per kilogram (kg) per hour (hr) (mL/kg/hr) for at least 25 minutes. The planned (...) : October 31, 2018 Last Update Posted : October 31, 2018 Sponsor: Alexion Pharmaceuticals Information provided by (Responsible Party): Alexion Pharmaceuticals Study Details Study Description Go to Brief Summary: The primary objective of this study was to evaluate the pharmacokinetic (PK) and pharmacodynamic (PD) parameter estimates of eculizumab to confirm the dose regimens for pediatric and adolescent participants with PNH. Condition or disease Intervention/treatment Phase Hemoglobinuria, Paroxysmal

2009 Clinical Trials

157. Study of Indomethacin Capsules to Treat Pain Following Surgery in Children Ages 6 to <17 Years of Age

Capsules high dose twice daily for up to three days Drug: Indomethacin Capsules high dose Outcome Measures Go to Primary Outcome Measures : Plasma Concentrations of indomethacin [ Time Frame: 0-12 hours after first dose of indomethacin ] The estimated typical value for clearance (tvCL) following a single indomethacin dose based on population pharmacokinetic (PopPK) modeling using sparse plasma concentration data in pediatric subjects. Secondary Outcome Measures : Safety of Indomethacin Capsules low (...) : Indomethacin Capsules low dose Drug: Indomethacin Capsules high dose Phase 2 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 30 participants Allocation: Non-Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment Official Title: A Phase IIA, Open-label, Safety and Pharmacokinetic Study of Indomethacin Capsules in Pediatric Subjects 6 to <17 Years of Age With Mild to Moderate Acute

2015 Clinical Trials

158. A Multicenter Study to Evaluate the Efficacy and Safety of Cinryze® for the Treatment of Acute Antibody-mediated Rejection in Participants With Kidney Transplant

respectively. Biological: Cinryze® Participants will receive 5000 Units of CINRYZE (50 millilitre [mL] of CINRYZE/ 50 mL of normal saline) on Day 1 and 2500 Units of CINRYZE (25 mL of CINRYZE/ 75 mL of normal saline) on Day 3, 5, 7, 9, 11, and 13 respectively. Placebo Comparator: Placebo Participants will receive 7 doses of matched placebo over 13 days of treatment. Drug: Placebo Participants will receive 7 doses of matched placebo over 13 days of treatment. Outcome Measures Go to Primary Outcome Measures (...) of the qualifying AMR episodes will be assessed. Time to Resolution of AMR Episodes [ Time Frame: Baseline to 48 months ] Time to resolution of AMR episodes will be assessed. Number of Participants Alive at 4 Years [ Time Frame: Year 4 ] Number of participants alive at 4 years will be assessed. Time to all-Cause Mortality [ Time Frame: Baseline to 48 months ] Time to all-cause mortality will be assessed. Number of Participants With Treatment-emergent Adverse Events (TEAEs) [ Time Frame: Baseline to 49 months

2015 Clinical Trials

159. Study of Diclofenac Capsules to Treat Pain Following Surgery in Children Ages 6 to <17 Years of Age

Pain, Postoperative Drug: Diclofenac Capsules low dose Drug: Diclofenac Capsules high dose Phase 2 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 30 participants Allocation: Non-Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment Official Title: A Phase IIA, Open-Label, Safety and Pharmacokinetic Study of Diclofenac Capsules in Pediatric Subjects 6 to <17 Years of Age (...) dose Diclofenac Capsules high dose three times daily for up to three days Drug: Diclofenac Capsules high dose Outcome Measures Go to Primary Outcome Measures : Plasma Concentration of Diclofenac [ Time Frame: 0-6 hours after first dose of diclofenac ] The estimated typical value for clearance (tvCl) following a single diclofenac dose based on population pharmacokinetic (PopPK) modeling using sparse plasma concentration data in pediatric subjects. Secondary Outcome Measures : Safety of Diclofenac

2015 Clinical Trials

160. "Palivizumab Therapy for RSV-bronchiolitis"

with an appropriately sized Aerochamber with mask attachment. Daily follow-up by study nurse by telephone is mandatory for 1 week after discharge and then once a week for 2 weeks thereafter. The patient could return to the pediatric emergency center earlier if needed. At all revisits for the same illness, nasopharyngeal swabs will be taken for RSV rapid antigen test and the result recorded. Study Intervention: Active arm: A single dose of IV palivizumab 15 mg per kilogram body weight (maximum dose =100 mg). Control (...) /treatment Phase Respiratory Syncytial Virus-bronchiolitis Drug: Palivizumab Other: Placebo Phase 3 Detailed Description: Setting: The study will be conducted between September 2014 and April 2018 in the short stay unit of the Pediatric Emergency Center (PEC) of Hamad General Hospital, the only pediatric emergency facility in the State of Qatar. The PEC serves an average of 280 000 patients annually and manages 42 beds in a short stay infirmary unit, to which patients are admitted if they are too ill

2015 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>